This interventional trial (n=120) aims to explore the neural circuit-specific mechanisms of ketamine’s effect on anhedonia and anxiety in individuals with major depressive disorder (MDD).
Conducted by the Icahn School of Medicine at Mount Sinai, the study investigates the acute and sustained effects of ketamine on sgACC activation and depression symptoms using ultra-high field 7-Tesla MRI.
Participants, aged 18 to 65, diagnosed with MDD according to DSM-5 criteria, will be recruited. They will receive either ketamine or a placebo infusion.
The primary outcome measure is sgACC response to the Incentive Flanker Task, with secondary measures assessing treatment-related changes in sgACC response.
The study started on January 31, 2024, and is expected to conclude by April 30, 2028.
Trial Details
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.Trial Number NCT06213324
Sponsors & Collaborators
Icahn School of Medicine at Mount SinaiThis company doesn't have a full profile yet, it is linked to a clinical trial.